|本期目录/Table of Contents|

[1]徐瑞彤,孙康俊,戴冠群,等.抗雌激素治疗对耐酪氨酸激酶抑制剂非小细胞肺癌细胞株抗增殖作用的机制探讨[J].医学研究与战创伤救治(原医学研究生学报),2017,19(06):581-586.[doi:10.3969/j.issn.1672-271X.2017.06.006]
　XU Rui-tong,SUN Kang-jun,DAI Guan-qun,et al.The antitumor effect of anti-estrogen therapy on non-small cell lung cancer cell lines with acquired resistance to EGFR-TKI[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2017,19(06):581-586.[doi:10.3969/j.issn.1672-271X.2017.06.006]
点击复制

抗雌激素治疗对耐酪氨酸激酶抑制剂非小细胞肺癌细胞株抗增殖作用的机制探讨()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第19卷
期数:
2017年06期
页码:
581-586
栏目:
出版日期:
2017-11-23

文章信息/Info

Title:
The antitumor effect of anti-estrogen therapy on non-small cell lung cancer cell lines with acquired resistance to EGFR-TKI
作者:
徐瑞彤1; 孙康俊2; 戴冠群1; 徐静3
作者单位：1. 210029南京，江苏省人民医院全科医学科；2.211166南京，南京医科大学公共卫生学院；3. 210029南京，江苏省人民医院肿瘤科
Author(s):
XU Rui-tong1; SUN Kang-jun2; DAI Guan-qun1; XU Jing3
(1.Department of General Practice，Jiangsu Province Hospital，Nanjing 210029，Jiangsu，China;2.School of Public Health，Nanjing Medical University，Nanjing 211166,Jiangsu，China;3.Department of Oncology，Jiangsu Province Hospital，Nanjing 210029,Jiangsu，China)
关键词:
氟维司群; 吉非替尼; 非小细胞肺癌; 表皮生长因子受体; 耐药
Keywords:
Gefitinib; Fulvestrant; Non-small cell lung cancer; Epidermal growth factor receptor; Acquired resistance
分类号:
R365；R735.37
DOI:
10.3969/j.issn.1672-271X.2017.06.006
文献标志码:
A
摘要:
目的探讨氟维司群逆转吉非替尼耐药非小细胞肺癌细胞株耐药性的可能性及其机制。方法分别用不同浓度的氟维司群和吉非替尼，单药以及联合对非小细胞肺癌细胞株H1975[含表皮生长因子受体（EGFR） L858R & T790m突变]、H1650（含EGFR Del E746-A750 & PTEN De突变）、PC-9（含EGFR Del E746-A750突变）细胞进行干预后，采用MTT法检测细胞增殖变化，Western blot法检测EGFR、雌激素受体（ER）、磷酸化表皮生长因子受体（p-EGFR）的蛋白表达。结果①H1975、H1650、PC-9肺癌细胞中均有EGFR及ER表达；②吉非替尼及氟维司群联合用药较单药可明显抑制H1975、H1650、PC-9肺癌细胞的增殖(P<0.001)；③H1975耐药细胞株内T790m突变型EGFR的磷酸化水平可以快速地被雌激素升高或被氟维司群抑制；④ 在酪氨酸激酶抑制剂（EGFR-TKI）获得性耐药的肺癌细胞株中雌激素、表皮生长因子（EGF）分别下调EGFR、ER的水平，氟维司群、吉非替尼分别上调EGFR、ER的水平。结论采用EGFR的靶向治疗与抗雌激素治疗相结合的治疗方案提高EGFR和ER阳性的EGFR-TKI获得性耐药的NSCLC的治疗效果在理论上是可行的。
Abstract:
ObjectiveTo investigate the antitumor effects of combination of gefitinib and fulvestrant on NSCLC cell lines with acquired resistance to gefitinib.MethodsThe antitumor effect of gefitinib and fulvestrant on the growth of NSCLC cell lines was observed at different concentrations by MTT assay. The expression levels of EGFR, ER and p-EGFR were determined by Western blot.Results① All three lung cancer cell lines expressed both EGFR and ERs although to different extents. ② Compared with treatment of either fulvestrant or gefitinib alone, drug combination obviously decreased proliferation of H1976,H1650 and PC-9 cells lines (P<0.001). ③ Rapid activations of EGFR pathway by estrogen were observed in H1975 cells with T790M mutation. ④ EGFR and ERs expression were down-regulated respectively in response to estrogen and EGF but up-regulated in response to fulvestrant and gefitinib in vitro.ConclusionThese results suggest that there is a functional crosssignaling between the EGFR/ER pathways in NSCLC with acquired resistance to gefitinib, possibly providing rationale for combining gefitinib with anti-estrogen therapy for advanced NSCLC treatment

参考文献/References:

[1]Ferlay J,Soerjomataram I,Dikshit R,et al. Cancer incidence and mortality worldwide: sources,methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer,2015,136(5):E359-E386.
[2]段纪俊,严亚琼,杨念念,等.中国恶性肿瘤发病与死亡的国际比较分析[J].中国医学前沿杂志,2016,8(7):17-23.
[3]Castaón E，Rolfo C，Vial D,et al. Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis[J].J Transl Med,2015,13:257.doi: 10.1186/s12967-015-0622-x.
[4]Lynch TJ,Bell DW,Sordella R,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to Gefitinib[J]. N Engl J Med,2004,350(21):2129-2139.
[5]Yarden Y,Sliwkowski MX. Untangling the ErbB signaling network[J]. Nat Rev Mol Cell Biol,2001,2(2):127-137.
[6]Tracy S,Mukohara T,Hansen M,et al. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer line H3255[J].Cancer Res,2004,64(20):7241-7244.
[7]Pao W,Miller VA,Politi KA,et al. Acquired resistance of lung adenocarcinomas to Gefitinib or Erlotinib is associated with a second mutation in the EGFR kinase domain[J]. PLoS Med，2005,2(3):e73.
[8]Engelman JA,Zejnullahu K,Mitsudomi T,et al. MET amplification leads to Gefitinib resistance in lung cancer by activating ERBB3 signaling[J]. Science，2007,316(5827):1039-1043.
[9]Kobayashi S,Boggon TJ,Dayaram T,et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib[J]. N Engl J Med， 2005,352(8):786-792.
[10]Gazdar AF,Shigematsu H,Herz J,et al. Mutations and addiction to EGFR: the Achilles ‘heal’ of lung cancers?[J] Trends Mol Med，2004,10(10):481-486.
[11]李小优,冯继锋.表皮生长因子受体基因与非小细胞肺癌的分子靶向治疗研究进展[J]. 医学研究生学报,2012,25(12):1311-1315.
[12]Pao W,Miller VA. Epidermal growth factor receptor mutations,small-molecule kinase inhibitors,and non-small-cell lung cancer: current knowledge and future directions[J]. J Clin Oncol，2005,23(11):2556-2568.
[13]Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer[J]. J Clin Oncol，2005,23(14):3235-3242.
[14]李静，武新虎.非小细胞肺癌EGFR-TKI耐药机制及耐药后治疗策略[J].医学研究生学报,2013,26(8):859-863.
[15]Giaccone G,Rodriguez JA. EGFR inhibitors: what have we learned from the treatment of lung cancer?[J] Nat Clin Pract Oncol，2005,2(11):554-561.
[16]Riely GJ,Politi KA,Miller VA,et al. Update on epidermal growth factor receptor mutations in non-small cell lung cancer[J]. Clin Cancer Res，2006,12(24):7232-7241.
[17]Johnson BE,Janne PA. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer[J]. Cancer Res，2005,65(17):7525-7529.
[18]Stabile LP,Lyker JS,Gubish CT,et al. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects[J]. Cancer Res， 2005,65(4):1459-1470.
[19]陈芳芳，李晓军.细胞凋亡在介导非小细胞肺癌耐药调节中的作用[J].东南国防医药,2015,17(3):286-289.
[20]Garon EB,Siegfried JM,Dubinett SM,et al. Result of TORI L-03,a randomized,multicenter Phase II clinical trial of erlotinib (E) or E + fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC)[J]. Cancer Res，2013,73(8):4664-4664.
[21]Traynor AM,Schiller JH,Stabile LP,et al. Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer.[J] Lung Cancer，2009,64(1):51-59.
[22]Daub H,Specht K,Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors[J]. Nat Rev Drug Discov 2004,3(12):1001-1010.
[23]Bogush TA,Dudko EA,Beme AA,et al. Estrogen receptors,antiestrogens,and non-small cell lung cancer[J]. Biochemistry (Mosc)，2010,75(12):1421-1427.
[24]Navaratnam S,Skliris G,Qing G,et al. Differential role of estrogen receptor beta in early versus metastatic non-small cell lung cancer[J]. Horm Cancer,2012,3(3):93-100.
[25]Stabile LP，Dacic S,Land SR,et al. Combined analysis of estrogen receptor β-1 and progesterone receptor expression identifies lung cancer patients with poor outcome[J]. Clin Cancer Res,2011,17(1): 154-164.
[26]Yun CH,Mengwasser KE,Toms AV,et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP[J]. Proc Natl Acad Sci USA,2008,105(6):2070-2075.
[27]Engelman JA,Mukohara T,Zejnullahu K,et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer[J]. J Clin Invest,2006,116(10):2695-2706.

相似文献/References:

[1]王毅,权琳.培美曲塞与顺铂联合吉非替尼治疗对非小细胞肺癌患者T细胞亚群及细胞因子的影响[J].医学研究与战创伤救治(原医学研究生学报),2020,22(01):43.[doi:10.3969/j.issn.1672-271X.2020.01.010]
　WANGYi,QUANLin.Effects of pemetrexed and cisplatin combined with gefitinib on T cell subsets and cytokines in patients with lung cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2020,22(06):43.[doi:10.3969/j.issn.1672-271X.2020.01.010]

备注/Memo

备注/Memo:
基金项目：江苏省六大人才高峰资助项目（2015-WSW-022）
更新日期/Last Update: 2017-11-20